Delsam Pharma distributed non-sterile, contaminated artificial tears and eye ointment made by its contract manufacturer, FDA found.
What happened
FDA inspected Delsam's Bronx facility from March 6 to March 24, 2023, after an inspection at its contract manufacturer, Global Pharma Healthcare Private Limited, found violative conditions. FDA tested intact samples and found four batches of Delsam Pharma's Artificial Tears and a batch of Artificial Eye Ointment non-sterile; container closure testing found 1 of 20 eye ointment units allowed microbiological ingress. FDA linked the products to a multistate Pseudomonas aeruginosa outbreak affecting more than 80 patients, with 4 deaths and at least 14 cases of vision loss.
What FDA found
FDA testing found four batches of Artificial Tears and one batch of Artificial Eye Ointment were not sterile and contained microorganisms.
FD&C Act section 501(a)(1), 21 U.S.C. 351(a)(1)FDA found the products were made under insanitary conditions at the contract manufacturer.
FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)Delsam received and distributed adulterated drugs in interstate commerce.
FD&C Act sections 301(a) and 301(c), 21 U.S.C. 331(a) and 331(c)FDA found the products were misbranded because they were not sterile.
FD&C Act section 502(j), 21 U.S.C. 352(j); 21 CFR 200.50FDA found the eye ointment label claimed sterile when the product was not sterile, making the labeling false or misleading.
FD&C Act section 502(a), 21 U.S.C. 352(a)Delsam lacked adequate procedures to ensure product quality and microbial freedom, qualify its supplier and contract manufacturer, and handle complaints.
21 CFR Parts 210 and 211
What FDA wants
FDA asks Delsam to respond in writing within 15 working days with the actions taken and CAPA, including a detailed plan to avoid receiving or delivering adulterated drugs, evaluate suppliers and contract manufacturers, audit suppliers, and fix complaint handling. FDA also asks Delsam to clarify whether it will resume drug distribution and to notify FDA before resuming.
Who should pay attention
- distributors and private-label brands of ophthalmic OTC drugs
- companies that rely on contract manufacturers for sterile drug products
- quality teams responsible for supplier qualification and complaint handling
This is a summary. Read the original letter on fda.gov.